Monomerization of dimeric IgG of intravenous immunoglobulin (IVIg) increases the antibody reactivity against intracellular antigens.

[1]  R. Lemieux,et al.  Therapeutic intravenous immunoglobulins. , 2005, Molecular immunology.

[2]  Y. Shoenfeld,et al.  IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients , 2005, Autoimmunity.

[3]  G. Dickneite,et al.  Hypotension with intravenous immunoglobulin therapy: importance of pH and dimer formation. , 2003, Biologicals : journal of the International Association of Biological Standardization.

[4]  H. Simon,et al.  IVIG – mechanisms of action , 2003, Allergy.

[5]  W. Sewell,et al.  Immunomodulatory action of intravenous immunoglobulin , 2002, Immunology.

[6]  F. Chiarini,et al.  The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders , 2002, Neurological Sciences.

[7]  S. Kaveri,et al.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. , 2001, The New England journal of medicine.

[8]  V. Hemming.  Use of Intravenous Immunoglobulins for Prophylaxis or Treatment of Infectious Diseases , 2001, Clinical Diagnostic Laboratory Immunology.

[9]  S. Kaveri,et al.  Induction of natural autoantibody activity following treatment of human immunoglobulin with dissociating agents. , 2001, Journal of autoimmunity.

[10]  J. Kovarik,et al.  Product Equivalence Study Comparing the Tolerability, Pharmacokinetics, and Pharmacodynamics of Various Human Immunoglobulin‐G Formulations , 2000, Journal of clinical pharmacology.

[11]  S. Kaveri,et al.  Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG , 2000 .

[12]  M. Sturzenegger,et al.  Adverse Effects of Intravenous Immunoglobulin Therapy , 1999, Drug safety.

[13]  A. Coutinho,et al.  Self-reactive antibodies (natural autoantibodies) in healthy individuals. , 1998, Journal of immunological methods.

[14]  M. Dalakas.  Intravenous Immune Globulin Therapy for Neurologic Diseases , 1997, Annals of Internal Medicine.

[15]  S. Lacroix-Desmazes,et al.  Modulation of autoimmune responses by intravenous immunoglobulin (IVIg) , 1997, Multiple sclerosis.

[16]  S. Kaveri,et al.  Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. , 1995, Journal of autoimmunity.

[17]  D. Tankersley.  Dimer Formation in Immunoglobulin Preparations and Speculations on the Mechanism of Action of Intravenous Immune Globulin in Autoimmune Diseases , 1994, Immunological reviews.

[18]  H. Lutz,et al.  Preferential formation of C3b-IgG complexes in vitro and in vivo from nascent C3b and naturally occurring anti-band 3 antibodies. , 1993, The Journal of biological chemistry.

[19]  S. Kaveri,et al.  A V region‐connected autoreactive subfraction of normal human serum immunoglobulin G , 1992, European journal of immunology.

[20]  M. Kazatchkine,et al.  Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). , 1992, Blood.

[21]  M. Kazatchkine,et al.  Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. , 1990, The Journal of clinical investigation.

[22]  K. Roux,et al.  A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. , 1990, Journal of immunology.

[23]  M. Kazatchkine,et al.  Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. , 1989, Journal of immunology.

[24]  M. Kazatchkine,et al.  Anti‐idiotypes against Autoantibodies in Normal Immunoglobulins: Evidence for Network Regulation of Human Autoimmune Responses , 1989, Immunological reviews.

[25]  V. Oxelius,et al.  Immunoglobulin G Subclass Distribution in Three Human Intravenous Immunoglobulin Preparations , 1989, Vox sanguinis.

[26]  F. Seiler,et al.  On the nature of IgG dimers. I. Dimers in human polyclonal IgG preparations: kinetic studies. , 1988, Behring Institute Mitteilungen.

[27]  G. Walter,et al.  On the nature of IgG dimers. II. Idiotype--anti-idiotype complexes of polyclonal and monoclonal origin: size distribution patterns and molecular geometries. , 1988, Behring Institute Mitteilungen.

[28]  R. Hamilton,et al.  Human IgG subclass measurements in the clinical laboratory. , 1987, Clinical chemistry.

[29]  P. Gronski.  IgG dimers in multidonor-derived immunoglobulins: aspects of generation and function. , 2006, Current pharmaceutical design.

[30]  S. Kaveri,et al.  Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. , 2000, Blood.

[31]  J. Finlayson,et al.  Immunoglobulin G dimer: an idiotype-anti-idiotype complex. , 1988, Molecular immunology.